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Novel Strategies for the Treatment of Depression
Background
Major depression is a common and complex ill-
ness that significantly diminishes quality of life.1 
It is estimated that 216 million people suffered 
from major depressive disorder (MDD) in 2015 
worldwide,2 and rates are predicted to increase 
due to an increase in incidence rates among 
younger individuals.3 MDD is one of the largest 
leading causes of health-related disability, and the 
most costly of all mental health disorders.4 
Currently, most pharmacological treatments tar-
get neurotransmitter activity in the brain and are 
known to have a delayed onset of effect as well as 
a range of side-effects. Further, it has been esti-
mated that up to 60% of patients with MDD 
experience some degree of nonresponse to these 
treatments.5 Therefore, identifying novel treat-
ment approaches is of key importance.
Gut feeling: randomized controlled  
trials of probiotics for the treatment of 
clinical depression: Systematic review  
and meta-analysis
Viktoriya Nikolova , Syed Yawar Zaidi, Allan H. Young, Anthony J. Cleare  
and James M. Stone
Abstract
Background: Recently the gut microbiota has attracted significant interest in psychiatric 
research due to the observed bidirectional gut–brain communication. A growing body of 
evidence from preclinical work has suggested that probiotics may be effective in reducing 
stress and anxiety and alleviating low mood. It is unclear to what extent these effects are seen 
in clinical populations. We aimed to identify all published evidence on the efficacy of probiotics 
as treatment for depression in clinically depressed populations.
Methods: Randomized controlled trials of patients with depression where probiotics were 
used as supplementary or standalone treatment were considered eligible. A literature search 
with the terms (probiotic* OR bacteria OR Lactobacillus OR Bifidobacterium) AND depress* was 
performed in PubMed and Web of Science. Data on study population characteristics, treatment 
effectiveness, tolerability and risk of bias were extracted from eligible studies. A random 
effects model was used for meta-analyses.
Results: Only three studies met inclusion criteria (229 individuals randomized), two of which 
administered probiotics as a supplementary treatment to antidepressants and one as a 
standalone treatment. Upon removal of the latter study from the meta-analysis due to clinical 
heterogeneity, there was an overall positive effect of probiotics on depressive symptoms 
(standardized mean difference = 1.371, 95% confidence interval 0.130–2.613).
Conclusions: There is limited evidence for the efficacy of probiotics in depression at present, 
although there may be a beneficial effect of probiotics on depressive symptoms when 
administered in addition to antidepressants. Further studies are required to investigate this 
and explore potential mechanisms.
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In recent years, a complex bidirectional communi-
cation between the gut and the brain has been iden-
tified, which has attracted significant interest in 
psychiatric research. The mechanisms underlying 
the gut–brain axis are thought to span the gastroin-
testinal tract, central nervous system (CNS), auto-
nomic nervous system, enteric nervous system, 
neuroendocrine system and immune system.6 A 
growing body of evidence suggests that psychiatric 
disorders such as MDD may be related to changes 
in the gut microbiota. For example, preclinical 
studies with germ-free mice (with no gut bacteria) 
have shown that these animals exhibit increased 
stress response and anxiety-like behaviours and 
deficits in social behaviour and memory – all of 
which are prominent features of depressive disor-
ders.7 These findings have also been replicated in 
mice given a mixture of antibiotics or with induced 
bacterial infection.8,9 These effects have been 
shown to be reversed by restoring commensal 
microbiota or by treatment with probiotics.7–9 
Other groups have investigated the effect of rodent 
models of depression on gut microbiota: Barseghyan 
and colleagues found significantly increased num-
bers of Candida albicans and Staphylococcus aureus 
and decreased numbers of Lactobacilli and 
Bifidobacteria in rats after 2 weeks of chronic varia-
ble stress.10 Similarly, Naseribafrouei and col-
leagues investigated the relationship between faecal 
microbiota and depression in patients with MDD, 
and discovered that MDD was associated with a 
specific pattern of overrepresentation of the order 
of bacteria Bacteroidales and an underrepresenta-
tion of the family Lachnospiraceae.11 Taken 
together, these findings suggest that gut bacteria 
may have a role in causing or maintaining depres-
sive disorders, and that probiotics may be a poten-
tial novel treatment approach.
Several studies have investigated the mood-alter-
ing properties of probiotic supplements in people 
without a clinical diagnosis of depression, and 
have found that these can reduce feelings of 
depression and anxiety, stress and cognitive reac-
tivity to sad mood.12–15 These studies have been 
reviewed extensively elsewhere.16,17 The accumu-
lated evidence from these studies supports the 
preclinical evidence that probiotics may be bene-
ficial for the treatment of low mood. However, for 
probiotics to be considered a viable treatment 
option for MDD or other affective disorders, evi-
dence from clinical trials in well-defined clinical 
populations is needed. The objective of this 
review was to identify and synthesize all published 
data from randomized controlled trials (RCTs) 
on the efficacy of probiotics as treatment for 
depression in clinically depressed patients.
Methods
Criteria for inclusion of studies in the review
Studies considered eligible for this review were 
peer-reviewed published RCTs where probiotics 
were administered as an active intervention for 
patients with clinical depression, and where the 
effects of probiotics on depressive symptoms were 
assessed as the primary outcome. Studies must 
have either targeted patients who were clinically 
diagnosed with MDD or used an appropriate 
measurement of depressive symptoms to deter-
mine that they are clinically depressed. Studies in 
which probiotics were administered for the treat-
ment of another disorder (e.g. irritable bowel syn-
drome) and where effects on depression were 
assessed as a secondary outcome were deemed 
not eligible for inclusion.
Search strategy
The literature search was performed according to 
PRISMA guidelines for systematic reviews.18 The 
search terms included [probiotic* OR bacteria OR 
Lactobacillus OR Bifidobacterium] AND [depress*] 
and the search was limited to human studies. The 
initial search was conducted on PubMed and ISI 
Web of Science databases on 11 May 2018 with no 
restrictions on date of publication. An additional 
search on Google Scholar was performed to iden-
tify any studies that may have been missed. This 
was further supplemented by reviewing the bibli-
ographies of relevant articles and recent reviews. 
All search results were evaluated against search cri-
teria independently by VN and SYZ, with discrep-
ancies resolved by JS. Data extraction of basic 
study characteristics, measures of treatment effect 
and tolerability, and quality assessment was con-
ducted by VN and SYZ and reviewed by JS.
Measures of treatment effect
Continuous data describing treatment effectiveness 
were extracted (i.e. pre- and post-treatment depres-
sion scores or change in depression score), and pre-
sented as a standardized mean difference (SMD; 
Hedge’s g). Values extracted were unadjusted for 
baseline due to unreported data. Using a random 
effects model, meta-analyses computed a pooled 
SMD with 95% confidence intervals (CI) and the 
I2 statistic assessing heterogeneity between studies. 
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Data were analysed with OpenMeta[Analyst].19 
Due to the small number of studies, sensitivity 
analysis was performed only on the basis of clinical 
heterogeneity and not statistical heterogeneity.
Quality assessment
Included trials were assessed for the quality of 
methodology employed and risk of bias using the 
SIGN (Scottish Intercollegiate Guidelines 
Network) tool evaluating nine main factors: (1) 
appropriateness of the research question; (2) ran-
domization; (3) concealment of allocation; (4) 
blinding; (5) comparability of groups at baseline; 
(6) comparability of follow-up (i.e. groups differ 
only according to treatment allocation, but no 
other factors that may influence outcome); (7) 
use of standardized measures, (8) use of inten-
tion-to-treat (ITT) analysis; and (9) differences 
between study sites.20 Overall risk of bias was 
rated as low, moderate or high.
Results
Systematic search results
Of the 485 records identified through all sources 
from the initial search, 433 were screened after 
removal of duplicates. Of these, 18 full-text arti-
cles were screened for eligibility, of which only 3 
met the predefined selection criteria (see Figure 1 
for PRISMA flowchart of the search process).
Characteristics of included studies
Within the three included RCTs, a total of 229 
clinically depressed patients were randomized, 
with an average age of 36 years and a gender dis-
tribution of 76% female. All three studies were 
parallel-group studies and included a placebo 
comparator arm. One study also included a prebi-
otic comparator arm.21 The length of intervention 
was 8 weeks across all studies, and in two studies 
the probiotic intervention was in addition to the 
patients’ ongoing antidepressant medication, 
while in one study patients were required to be 
psychiatric medication-free.22 Two of the trials 
were conducted in Iran and one in New Zealand. 
The key characteristics of the included studies are 
summarized in Table 1.
Quality assessment
Overall, the risk of bias assessment of the three 
RCTs was low/moderate. Two issues were 
identified: Akkasheh and colleagues did not report 
baseline depression severity for each group,23 
which is a key variable that may influence study 
findings and should have been presented; Romijn 
and colleagues reported a significant difference in 
antidepressant history at baseline between groups, 
with 70% versus 46% of previous use reported in 
the probiotics and placebo group, respectively.22 
However, the groups did not differ on current 
depression severity, or on chronicity (defined as 
>2 years continuous symptoms). The groups also 
differed in rates of irritable bowel syndrome symp-
toms at baseline, with the probiotic group scoring 
significantly higher. A breakdown of the quality 
assessment by study is presented in Table 2.
Effects of probiotic treatment on depressive 
symptoms
Overall, there was a nonsignificant difference in 
depressive symptoms between the probiotic and 
placebo groups postintervention (SMD = 0.826, 
95% CI −0.527 to 2.178, p = 0.231; I2 = 94.7), 
with high heterogeneity between the studies 
observed (Figure 2).
Akkasheh and colleagues found a significant dif-
ference in Beck Depression Inventory (BDI) 
scores after 8 weeks of add-on treatment with pro-
biotics, with mean reduction of BDI total score of 
−5.7 in the probiotics group compared with −1.5 
in the placebo group (p = 0.001).23 When adjusted 
for baseline levels, this effect remained significant 
(p = 0.05). Kazemi and colleagues also reported a 
Figure 1. PRISMA flow chart presenting a breakdown 
of the search process.
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significant decrease in BDI total score in the 
group receiving probiotics, with a mean reduction 
of −9.25 compared with −3.19 in the group 
receiving placebo after 8 weeks of add-on treat-
ment (p = 0.008).21 Romijn and colleagues found 
no significant difference between probiotic and 
placebo treatment groups in Montgomery-Asberg 
Depression Scale (MADRS) total score after 
8 weeks of primary treatment with probiotics, 
with a mean change in MADRS total score of 
−8.7 in the probiotic group and −9.7 in the pla-
cebo group (adjusted for baseline; p = 0.62).22
Sensitivity analysis
The study by Romijn and colleagues differed 
from the other two trials in that individuals were 
not taking any antidepressant medication at the 
Table 1. Summary of key characteristics of the included randomized clinical trials (RCTs) (arranged by year of publication).
First author 
(year)
Sample Sample 
size
Intervention 
type
Intervention 
length
Probiotic strains (CFU)/g 
and dose
Control
arm(s)
Outcome 
measure
Akkasheh 
(2016)23
MDD 
patients
aged 20–55
40 Add-on 8 weeks Lactobacillus acidophilus 
(2 × 109 )
Lactobacillus casei (2 × 109 )
Bifidobacterium bifidum 
(2 × 109)/g
1 capsule daily
placebo BDI
Romijn 
(2017)22
Self-
referrals 
with at least 
moderate 
depression 
score;
aged >16
79 Mono-
therapy
8 weeks Lactobacillus helveticus
Bifidobacterium longum
(⩾2 × 109)/g
1.5 g sachet daily
placebo MADRS
Kazemi 
(2019)21
MDD 
patients
aged 18–50
110 Add-on 8 weeks L. helveticus
B. longum
(⩾2 × 109)/g
5 g sachet daily
placebo
prebiotic
BDI
BDI, Beck Depression Inventory; CFU, colony-forming unit; MADRS, Montgomery-Asberg Depression Scale.
Table 2. Methodological quality and risk of bias in the included trials.
Criterion Akkasheh et al.23 Romijn et al.22 Kazemi et al.21
Appropriateness and focus of study question + + +
Assignment to treatment groups is randomized + + +
Adequate concealment of allocation + + +
Patients, clinicians and assessors are blinded + + +
Similarity of groups at baseline ? – +
Comparability of groups during treatment period + + +
Use of standardized outcome measure + + +
Intent-to-treat analysis + + +
Comparability between study sites n/a n/a n/a
Overall assessment or risk of bias low/moderate low/moderate low
V Nikolova, SY Zaidi et al.
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time of the study.22 Furthermore, individuals 
were recruited by advertising and were not for-
mally assessed using a diagnostic scale for depres-
sion, although they did self-report symptoms 
consistent with moderate MDD. Due to this clin-
ical heterogeneity. we repeated the meta-analyses 
after excluding this study, which yielded a signifi-
cant effect of probiotics on reducing depressive 
symptoms (SMD = 1.371, 95% CI 0.130–2.613, 
p = 0.03; I2 = 88.3); however, heterogeneity 
remained high. On the basis of reported study 
and sample characteristics in the remaining two 
RCTs, no cause for further clinical heterogeneity 
could be identified.
Tolerability and adherence
Overall, probiotic supplements were well toler-
ated with no related serious adverse events (AEs) 
reported and a low drop-out rate in all studies. 
Akkasheh and colleagues did not report AE 
data.23 The most commonly reported AEs in the 
remaining two studies were gastrointestinal com-
plaints, nausea and change in appetite. The rates 
of these did not differ significantly between 
groups in the study by Romijn and colleagues; the 
only AEs that were significantly different were dry 
mouth and sleep disruption, with higher rates 
reported in the placebo group.22 Kazemi and col-
leagues reported AEs occurring in 10 participants 
in the probiotic group and 1 in the placebo group; 
no comparative analyses were reported, likely due 
to the low AE rates observed.21 Adherence was 
high across all studies, with supplement counts 
showing between 90–97% of doses taken.
Discussion
Evidence from animal models and healthy  volunteer 
studies suggests that probiotics may be beneficial 
for alleviating stress, anxiety and depressive symp-
toms. In this systematic review we aimed to identify 
all RCT data on the efficacy of probiotics as treat-
ment for depressive symptoms in clinically 
depressed patients. Only three RCTs met our 
inclusion criteria, suggesting that there is still an 
insufficient evidence base. The duration of inter-
vention in all three studies was 8 weeks, and a 
standardized measure of depressive symptoms was 
employed as a primary outcome measure. 
Adherence to the intervention and tolerability were 
high in all studies. Overall, there was a nonsignifi-
cant difference in depressive symptoms between 
the probiotic and placebo groups postintervention. 
However, as discussed in the sensitivity analysis, 
two of the studies, which administered probiotics 
as add-on to ongoing antidepressant therapy in 
patients with MDD, reported that probiotic sup-
plements significantly improved depression scores 
compared with placebo.21,23 In contrast, the third 
study, which administered probiotics as a stan-
dalone treatment in medication-free patients with 
self-rated moderate-to-severe depressive symp-
toms, reported no significant difference between 
the probiotic and placebo arms.22
In the study by Romijn and colleagues,22 patients 
self-referred to the study and completed self-
rated depression measures during an online 
screening process. A minimum of moderate 
depression severity was a requirement for inclu-
sion; however, a formal diagnostic interview or 
screening of medical records was not performed 
at baseline. Instead, current depressive state and 
illness history were established entirely by self-
report and retrospective self-report. As the 
screening measures used have been well-vali-
dated in the field, this population was considered 
to meet criteria for clinical depression and was 
included in this review. As ‘depression’ is an 
Figure 2. Forest plot showing standardized mean difference in depressive symptoms, comparing probiotic and 
placebo.
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umbrella term used for multiple disorders, the 
context in which participants were experiencing 
depressive symptoms is not clear, suggesting that 
this was likely to have been a heterogeneous pop-
ulation. This potential heterogeneity of the sam-
ple may have been a contributing factor to the 
lack of significance of the main effect, and also 
impedes the clear interpretation of the findings. 
Removal of the Romijn study revealed a signifi-
cant effect of probiotics as an add-on to antide-
pressant treatment on depression. It will be 
important to replicate this, and to determine the 
underlying mechanisms explaining why add-on 
therapy may be effective whereas monotherapy is 
not. Similarly, to evaluate other potential clinical 
sources of variance, it would have been informa-
tive if the two add-on studies provided data on 
the duration, dose and level of prior response to 
the ongoing antidepressant treatment. Further, 
baseline depression severity was not reported in 
one of these studies,23 which may have contrib-
uted to the high heterogeneity observed here and 
also increases the risk of bias. It is not possible to 
say at this stage whether probiotics may be effec-
tive for all severities of depression.
The probiotic supplements used in the three 
RCTs, and in previously published studies, vary 
significantly, which reflects the lack of consensus 
in the field as to which specific strains/combina-
tions of strains are most likely to produce antide-
pressant effects. Strains from the Lactobacilli and 
Bifidobacteria genera have most frequently shown 
beneficial effects in animal studies and nonclini-
cal populations.16 The selection of bacteria in the 
three RCTs was also based on this evidence. 
Further studies in clinical populations are needed 
to identify the optimal content, dosing and dura-
tion of probiotic supplement treatment. Some 
have suggested that research needs to focus on 
identifying specific strains that are related to spe-
cific symptoms,16 although this is likely to be 
challenging due to the complexity of interactions 
within the gut. Further studies investigating 
potential antidepressant mechanisms of different 
strains of probiotic bacteria in humans are needed.
Strengths and limitations
A key strength of this review is the clear and rigor-
ous study selection criteria. Previous reviews have 
included all studies in humans, irrespective of ill-
ness status or design, which is of limited value in 
determining the clinical utility of probiotics for the 
treatment of depression. To our knowledge, this is 
the first study systematically evaluating evidence 
on the effectiveness of probiotics in clinically 
depressed individuals. The limitations of this 
review stem from the limited number of published 
RCTs. As described above, there was heterogene-
ity between the studies, which reduces the capac-
ity to draw clinically meaningful conclusions, 
including: type of intervention (add-on versus 
standalone), intervention content (strain combi-
nations and dosing), patient population (con-
firmed diagnosis of MDD versus self-report), 
depression severity threshold for inclusion (mild 
versus moderate), and AE reporting (one study did 
not report AE rates). Further, due to the different 
exploratory analyses performed in each trial, the 
evidence base regarding the mechanisms of action 
of probiotics in clinically depressed patients 
remains too limited for comparative analyses.
Conclusion
There is a limited amount of evidence for the effi-
cacy of probiotics in clinical depression, although 
the published data suggest there may be a benefi-
cial effect of probiotics on depressive symptoms 
in MDD when administered as an add-on to anti-
depressants. Further larger studies in well-defined 
clinical populations are needed, both to deter-
mine the clinical utility of this novel treatment 
approach, and to investigate potential underlying 
mechanisms.
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